RAG-Catalyzed V(D)J Targeting for Safe Gene Insertion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy methods for cancer and autoimmune diseases face challenges such as reliance on cumbersome ex vivo manipulations, risk of insertional mutagenesis, and limited scalability, particularly in large-scale applications and B cell engineering, due to the use of promiscuous integrating vectors and nucleases.
Innovation Solution
The method employs V(D)J targeting, utilizing recombinant adeno-associated virus (rAAV) vectors and RAG-catalyzed recombination to facilitate specific insertion of nucleic acid sequences into target genomic loci in developing lymphocytes, allowing for safe and efficient engineering of T cells and B cells for immunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If promiscuous integrating vectors and nucleases are used for gene targeting, then gene insertion can be achieved, but insertional mutagenesis and oncogene activation risks increase
Solution Approach 1:
The patent applies local quality by using site-specific integrating vectors that target predetermined safe harbor loci (such as Ig heavy chain, Ig light chain, or TCR loci) rather than promiscuous integration. This ensures gene insertion occurs only at specific locations with known low mutagenesis risk, while maintaining the ease of manufacture through defined targeting mechanisms. The RAG-mediated V(D)J recombination system provides localized precision at immunogenic loci, eliminating off-target effects.
2Ease of manufacture
If ex vivo manipulations are used for T cell engineering, then immunotherapy can be produced, but scalability and cost-effectiveness are limited
Solution Approach 1:
The patent enables self-service by allowing in vivo gene targeting within the lymphoid organs (thymus and bone marrow) where the immune system naturally operates. The RAG complex, endogenously expressed in developing lymphocytes, mediates V(D)J recombination without requiring external manipulation. This intrinsic mechanism enables scalable production of engineered T and B cells directly in the body, eliminating the need for cumbersome ex vivo processing facilities and significantly improving productivity.
3Manufacturing precision
If nucleases are used for gene targeting, then specific locus modification is achieved, but off-target effects and genomic instability increase
Solution Approach 1:
The patent replaces the mechanical nuclease-based cutting system with a biochemical recombination system. Instead of using nucleases to create double-strand breaks at target loci, the invention employs RAG-mediated V(D)J recombination that utilizes programmed DNA breaks and joining mechanisms inherent to lymphocyte development. This substitution eliminates off-target cutting effects while maintaining locus-specific precision, as the RAG system naturally targets immunogenic loci through recognition of specific signal sequences flanking gene segments.
4Ease of manufacture
If promiscuous integrating vectors are used, then gene transfer is achieved, but safety and efficacy are compromised
Solution Approach 1:
The patent applies local quality by replacing promiscuous gene transfer with site-specific integration at predetermined safe harbor loci. The integrating vectors are designed to target specific loci (Ig heavy chain, Ig light chain, TCR alpha, TCR beta) that are known to be safe for insertion, avoiding random integration that could activate oncogenes. This localized approach maintains ease of manufacture through defined targeting while dramatically improving safety and reliability by eliminating off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables precise and stable expression of immune genes, reducing the risk of off-target effects and oncogene activation, while enabling scalable and cost-effective immunotherapy that can be applied in community clinics, with improved safety and efficacy compared to existing technologies.
Implementation Method 1
The insertion of the nucleic acid sequence of interest into the target genomic locus is facilitated, mediated and performed by RAG-catalyzed recombination between at least one genomic RSS flanking the target genomic locus and at least one RSS comprised within the nucleic acid cassette
Implementation Method 2
The method employs V(D)J targeting, utilizing recombinant adeno-associated virus (rAAV) vectors and RAG-catalyzed recombination to facilitate specific insertion of nucleic acid sequences into target genomic loci in developing lymphocytes
Data Source
AI summary
The present invention relates to methods for targeted insertion of at least one nucleic acid sequence/s of interest into a target genomic locus of a mammalian cell. More specifically, the methods of the invention are based on using nucleic acid cassettes comprising the nucleic acid sequence/s of interest and at least one recognition signal sequence (RSS), for insertion of the nucleic acid sequence of interest into the target genomic locus that is mediated by RAG-catalyzed recombination. The invention further provides cassettes, vectors and vehicles and cells comprising said cassettes, compositions and uses thereof in immunotherapy.